InspireMD, Inc.
NSPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | 0.05 | -0.02 | 0.02 |
| FCF Yield | -21.10% | -24.57% | -236.56% | -61.10% |
| EV / EBITDA | -2.82 | -2.88 | -0.20 | -0.78 |
| Quality | ||||
| ROIC | -84.61% | -50.29% | -93.70% | -41.25% |
| Gross Margin | 21.49% | 29.12% | 21.60% | 16.77% |
| Cash Conversion Ratio | 0.68 | 0.82 | 0.84 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.67% | 11.34% | 27.67% | 6.50% |
| Free Cash Flow Growth | -38.87% | -4.63% | -18.16% | -47.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.50 | 0.38 | 0.16 | 0.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -93.73 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 2.09 | 2.50 | 3.27 |
| Cash Conversion Cycle | 204.67 | 241.09 | 174.63 | 137.18 |